- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Alexion Pharmaceuticals is a biotechnology business based in the US. Alexion Pharmaceuticals shares (ALXN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $176.55 – a decrease of 0.31% over the previous week. Alexion Pharmaceuticals employs 3,837 staff and has a trailing 12-month revenue of around $6.3 billion.
What's in this guide?
- ALXN shares summary
- Compare share dealing platforms
- Is ALXN stock a buy or sell?
- Stock performance over time
- Can I short ALXN shares?
- Are ALXN shares over-valued?
- Alexion Pharmaceuticals's financials
- How volatile are ALXN shares?
- Does Alexion Pharmaceuticals pay a dividend?
- Have ALXN shares ever split?
- Other common questions
Our top picks for where to buy Alexion Pharmaceuticals stock
- Trade $0 commission stocks & ETFs with as little as $1
- Theme and ETF screener
- Discover new opportunities with Opto's AI-driven classification system
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
How to buy Alexion Pharmaceuticals stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ALXN. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Alexion Pharmaceuticals stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Alexion Pharmaceuticals stock price (NASDAQ: ALXN)
Use our graph to track the performance of ALXN stocks over time.Alexion Pharmaceuticals shares at a glance
Latest market close | $176.55 |
---|---|
52-week range | $0.00 - $0.00 |
50-day moving average | $182.75 |
200-day moving average | $165.77 |
Wall St. target price | $177.36 |
PE ratio | 59.234 |
Dividend yield | N/A |
Earnings per share (TTM) | $3.08 |
Is it a good time to buy Alexion Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Alexion Pharmaceuticals price performance over time
Historical closes compared with the close of $176.55 from 2021-05-28
1 week (2024-10-18) | N/A |
---|---|
1 month (2024-09-25) | N/A |
3 months (2024-07-25) | N/A |
6 months (2024-04-25) | N/A |
1 year (2023-10-25) | N/A |
---|---|
2 years (2022-10-25) | N/A |
3 years (2021-10-25) | N/A |
5 years (2019-10-29) | 64.25% |
Is Alexion Pharmaceuticals stock undervalued or overvalued?
Valuing Alexion Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Alexion Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Alexion Pharmaceuticals's P/E ratio
Alexion Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 59x. In other words, Alexion Pharmaceuticals shares trade at around 59x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Alexion Pharmaceuticals's PEG ratio
Alexion Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.1706. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Alexion Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Alexion Pharmaceuticals's EBITDA
Alexion Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.3 billion.
The EBITDA is a measure of a Alexion Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Alexion Pharmaceuticals financials
Revenue TTM | $6.3 billion |
---|---|
Operating margin TTM | 47.41% |
Gross profit TTM | $5.5 billion |
Return on assets TTM | 10.08% |
Return on equity TTM | 4.43% |
Profit margin | 10.89% |
Book value | $56.21 |
Market Capitalization | $40.3 billion |
TTM: trailing 12 months
Alexion Pharmaceuticals's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Alexion Pharmaceuticals.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Alexion Pharmaceuticals's total ESG risk score
Total ESG risk: 28.21
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Alexion Pharmaceuticals's overall score of 28.21 (as at 12/31/2018) is pretty good – landing it in it in the 26th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Alexion Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Alexion Pharmaceuticals's environmental score
Environmental score: 8.12/100
Alexion Pharmaceuticals's environmental score of 8.12 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Alexion Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Alexion Pharmaceuticals's social score
Social score: 17.78/100
Alexion Pharmaceuticals's social score of 17.78 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Alexion Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Alexion Pharmaceuticals's governance score
Governance score: 15.31/100
Alexion Pharmaceuticals's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that Alexion Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Alexion Pharmaceuticals's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Alexion Pharmaceuticals scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Alexion Pharmaceuticals has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Alexion Pharmaceuticals Inc was last rated for ESG on: 2019-01-01.
Total ESG score | 28.21 |
---|---|
Total ESG percentile | 26.48 |
Environmental score | 8.12 |
Environmental score percentile | 9 |
Social score | 17.78 |
Social score percentile | 9 |
Governance score | 15.31 |
Governance score percentile | 9 |
Level of controversy | 2 |
Alexion Pharmaceuticals share dividends
We're not expecting Alexion Pharmaceuticals to pay a dividend over the next 12 months.
Have Alexion Pharmaceuticals's shares ever split?
Alexion Pharmaceuticals's shares were split on a 2:1 basis on 22 May 2011 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Alexion Pharmaceuticals shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Alexion Pharmaceuticals shares which in turn could have impacted Alexion Pharmaceuticals's share price.
Alexion Pharmaceuticals share price volatility
Over the last 12 months, Alexion Pharmaceuticals's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alexion Pharmaceuticals's is 1.2595. This would suggest that Alexion Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Alexion Pharmaceuticals overview
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally.
Frequently asked questions
nullWhat percentage of Alexion Pharmaceuticals is owned by insiders or institutions?
Currently 0.268% of Alexion Pharmaceuticals shares are held by insiders and 88.023% by institutions. How many people work for Alexion Pharmaceuticals?
Latest data suggests 3,837 work at Alexion Pharmaceuticals. When does the fiscal year end for Alexion Pharmaceuticals?
Alexion Pharmaceuticals's fiscal year ends in December. Where is Alexion Pharmaceuticals based?
Alexion Pharmaceuticals's address is: 121 Seaport Boulevard, Boston, MA, United States, 02210 What is Alexion Pharmaceuticals's ISIN number?
Alexion Pharmaceuticals's international securities identification number is: US0153511094 What is Alexion Pharmaceuticals's CUSIP number?
Alexion Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 015351109
More guides on Finder
-
Best broker cash sweep rates of 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
Trading for Beginners: 9 Best Trading Platforms to Get Started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
SoFi Invest vs. Robinhood
Compare pros, cons, research tools and reviews for these two trading platforms.
-
10 Best Stock Apps of 2024 to Elevate Your Mobile Trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
10 Best Brokerage Accounts for Trading and Investing in 2024
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
-
SoFi Invest® review 2024: Simple investing, free CFP access
SoFi Invest is a commission-free platform with both active and automated investment accounts.
-
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
-
How to Invest $20K: 8 Ways to Maximize Earnings
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
-
Robinhood Review 2024: IRA Match and No Commissions
A deep dive into the highlights and limitations of Robinhood.
Ask a question